Table_1.PDF Kirsten Geneugelijk Matthias Niemann Julia Drylewicz Arjan D. van Zuilen Irma Joosten Wil A. Allebes Arnold van der Meer Luuk B. Hilbrands Marije C. Baas C. Erik Hack Franka E. van Reekum Marianne C. Verhaar Elena G. Kamburova Michiel L. Bots Marc A. J. Seelen Jan Stephan Sanders Bouke G. Hepkema Annechien J. Lambeck Laura B. Bungener Caroline Roozendaal Marcel G. J. Tilanus Joris Vanderlocht Christien E. Voorter Lotte Wieten Elly M. van Duijnhoven Mariëlle Gelens Maarten H. L. Christiaans Frans J. van Ittersum Azam Nurmohamed Junior N. M. Lardy Wendy Swelsen Karlijn A. van der Pant Neelke C. van der Weerd Ineke J. M. ten Berge Fréderike J. Bemelman Andries Hoitsma Paul J. M. van der Boog Johan W. de Fijter Michiel G. H. Betjes Sebastiaan Heidt Dave L. Roelen Frans H. Claas Henny G. Otten Eric Spierings 10.3389/fimmu.2018.00321.s001 https://frontiersin.figshare.com/articles/dataset/Table_1_PDF/5947114 <p>Individual HLA mismatches may differentially impact graft survival after kidney transplantation. Therefore, there is a need for a reliable tool to define permissible HLA mismatches in kidney transplantation. We previously demonstrated that donor-derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation after kidney transplantation. In the present Dutch multi-center study, we evaluated the possible association between PIRCHE-II and kidney graft failure in 2,918 donor–recipient couples that were transplanted between 1995 and 2005. For these donors–recipients couples, PIRCHE-II numbers were related to graft survival in univariate and multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% CI: 1.04–1.23, p = 0.003]. When analyzing a subgroup of patients who had their first transplantation, the HR of graft failure for ln(PIRCHE-II) was higher compared with the overall cohort (HR: 1.22, 95% CI: 1.10–1.34, p < 0.001). PIRCHE-II demonstrated both early and late effects on graft failure in this subgroup. These data suggest that the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft survival.</p> 2018-03-05 04:10:21 PIRCHE-II kidney transplantation graft rejection HLA antigens HLA matching